Current Trials available at Adelaide Oncology & Haematology

Tumour Type

Trial

Principal Investigator

Title

Melanoma

PISCES

Roberts-Thomson

A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment

Melanoma

Nectar

Roberts-Thomson

A Phase 3, Randomized, Open-Label study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma

CRC

CA209-8HW

Joshi

A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer

Breast

CA209-7FL

Joshi

A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

NSCLC

MK-7902-008

Joshi

A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (LEAP-008)

NSCLC

MS200647-0005

Joshi

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer

NSCLC

ARCUS

Joshi

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line Non-Small Cell Lung Cancer

NSCLC with weight loss

ANAM-17-21

Kwatra

A phase 3, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC.

Variety

SPARTA

Kwatra

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NOTE: Pre-screening PICF and trial c-Met testing available for NSCLC and GBM patients.

TNBC

OMS-I141

Joshi

A phase 2, multi-cohort, open-label study of intratumoral tavokinogene telseplasmid plus electroporation in combination with intravenous pembrolizumab therapy with or without chemotherapy in patients with inoperable locally advanced or metastatic triple negative breast cancer

Prostate

CA209-7DX

Kwatra

A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer

Bladder

CA017-078

Joshi

A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer

NSCLC

Pyrotinib

Joshi

A Phase 3, Randomized, Open-label, Multicentre Study of the Efficacy and Safety of Pyrotinib versus Docetaxel in Patients with Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation who Progressed on or after Treatment with Platinum Based Chemotherapy

Multiple Myeloma

Dream 3

Jaksic

A Phase III, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)